Consumer group challenges Gilead patents on hepatitis C drug
Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty
Under-the-radar SCOTUS patent case could have big implications for drug prices, access
Patents, Licenses and Drug Prices
DEEP DIVE OPINION: Increasing access to medicines: A critical look at pharmaceutical patents

Patently Dumb: America’s current patent system inhibits innovation. Here’s how to fix it
Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries
AbbVie’s New Hepatitis C Treatment Won’t Cure Patient Access Issue
WHO moves to widen access to generic Sovaldi in dozens of countries